New evidence for use of anti-inflammatory therapy for prevention of recurrent vascular events in stroke

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organization Conference (ESOC 2024), anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis. Reduced event rates in secondary analyses, and in the subgroup of patients with coronary artery disease, support trials which reported benefit in coronary disease and may inform future secondary prevention trials in stroke. Inflammation plays an important role in the pathophysiology of atherosclerosis. Over the past years, Read More